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Objectives. This report describes the results of the Food and
Drug Administration’s phase 1 and 2 clinical trials of intravas-
cular stents at Texas Children’s Hospital.
Background. Since the late 1980s, intravascular stent implan-
tation for the treatment of arterial and venous stenoses in
congenital heart disease has been highly successful.
Methods. Stents were placed in postoperative pulmonary artery
(PA) stenoses, congenital PA stenoses or stenoses of systemic
veins/venous anastomoses. Prospective collection of data accord-
ing to protocol was done before intervention, after stent implan-
tation and at follow-up catheterization.
Results. At stent implantation, pressure gradients decreased
significantly in all three groups (mean 6 SD): from 46 6 25 to 10 6
13 mm Hg in postoperative PA stenoses (p < 0.001); from 71 6 45 to
15 6 21 mm Hg in congenital PA stenoses (p < 0.001); and from 7 6
6 to 1 6 2 mm Hg in stenoses of systemic veins/venous anastomoses
stenoses (p < 0.001). Vessel diameters markedly increased: from 6 6
3 to 12 6 3 mm in postoperative PA stenoses (p < 0.001); from 3 6
1 to 9 6 1 mm in congenital PA stenoses (p < 0.001); and from 3 6
4 to 12 6 4 mm in stenoses of systemic veins/venous anastomoses
(p < 0.001). In the postoperative and congenital PA stenoses groups,
right ventricular pressure decreased (right ventricular pressure
indexed to femoral artery pressure ratio): from 0.63 6 0.2 to 0.41 6
0.02 (p < 0.001) and from 0.71 6 0.3 to 0.55 6 0.35 (p 5 0.04),
respectively. Perfusion to a single affected lung increased from 31 6
17% to 46 6 14% (p < 0.001). On recatheterization (mean 14
months), results varied minimally. Repeat angioplasty of residual
stent stenoses was safe and effective. Complications included four
early patients with stent migration, three with stent thrombosis and
two deaths. There were no late complications. Significant restenosis
occurred in only three patients.
Conclusions. Intravascular stents for the treatment of vascular
stenoses in congenital heart disease provide excellent immediate
and long-term results.
(J Am Coll Cardiol 1998;31:661–7)
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Vascular stenoses in patients with congenital heart disease can
be the cause of significant morbidity and mortality. In patients
with either congenital or postoperative branch pulmonary
artery (PA) stenoses, elevated right ventricular (RV) pressure
is associated with RV failure, arrhythmias and sudden death
(1,2). Within the venous system, hemodynamically significant
stenoses, including cavopulmonary anastomoses, can contrib-
ute to superior vena cava syndrome, poor passive flow with
poor cardiac output and atrial arrhythmias. Elevated central
venous pressures in these patients is a risk factor associated
with higher mortality (3). To our knowledge, no Food and
Drug Administration (FDA)-approved treatment for vascular
stenoses in patients with congenital heart disease has previ-
ously been described.
Mullins et al. (4) first studied the use of balloon-expandable
intravascular stents in pulmonary arteries and systemic veins in
the late 1980s. The purposes of stent implantation were to
dilate areas of stenoses using angioplasty balloons matched to
the appropriate size of the adjacent vessel and to provide a
support structure at the area of stenosis to prevent recoil.
These stents could be delivered to distal branches not accessi-
ble surgically or within previously scarred areas of stenosis
“from the inside,” obviating the need for a repeat operation
and its associated complications. After the initial animal
studies, the investigators proceeded to the FDA clinical trials
under an Investigational Device Exemption (IDE). These data
are the basis of this report. There have been early serial reports
about the gratifying immediate results in the phase one and
two clinical trials of intravascular stents in congenital heart
disease (5–7). Likewise, other investigators have reported
successful treatment of vascular stenoses with this procedure
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(8). The purpose of this study was to illustrate the safety and
efficacy of intravascular stents in the treatment of vascular
stenoses in patients with congenital heart disease. This report
summarizes the results of the only FDA-approved IDE study
of balloon-expandable stents in patients with congenital heart
disease and contains both early data previously reported and
new data on more recent cases, including the long-term
follow-up data on all patients.
Methods
The patients were enrolled after parental (and, when
applicable, patient) written informed consent was obtained.
Data were collected under a U.S. FDA-IDE protocol for phase
one and two clinical trials. The Institutional Review Boards of
Baylor College of Medicine and Texas Children’s Hospital
approved the protocol, and procedures followed were in
accordance with institutional guidelines.
All patients enrolled in the study had vascular stenoses that
required balloon angioplasty or surgical repair—specifically,
significant stenoses in branch PAs, stenoses in RV to PA
conduits and stenoses in systemic veins (including cavopulmo-
nary anastomoses) or other postoperative venous channels.
Between September 1989 and June 1995, 200 patients under-
went cardiac catheterization with placement of a total of 347
stents. To provide uniformity of initial and follow-up data, this
report does not include initial phase one data on 30 additional
patients treated at Children’s Hospital in Boston. The Palmaz
stent (Johnson and Johnson Interventional Systems) was used
in all patients; most stents were model P-308 (3 cm long,
3.4 mm nominal diameter, expandable to 12 to 18 mm). Later
in the study, model P-204 stents (2.0 cm long, 2.5 mm nominal
diameter, expandable to 8 to 10 mm) were used to treat
stenoses in smaller, more distal vessels.
The technique for stent delivery and implantation has been
extensively described previously (4–8). In brief, most patients
have diagnostic catheterization under conscious sedation.
Rare, higher risk patients require general anesthesia. Standard
venous sheaths are then replaced with a larger diameter, long
(“transseptal”) sheath over a stiff, exchange-length wire previ-
ously anchored across the stenosis. Patients are anticoagulated
with 50 to 100 U/kg body weight after the initial activated
clotting time is measured. Heparin was not reversed routinely,
unless the activated clotting time was .350 s at the end of the
procedure.
Stents are mounted on low pressure angioplasty balloons
sized not to exceed the diameter of the vessel adjacent to the
stenosis. The long sheath is advanced through the area of
stenosis, and the balloon–stent assembly is advanced within the
sheath to the level of stenosis. The sheath is withdrawn,
exposing the balloon and stent. Confirmatory angiography
documents the position of the stent before inflation of the
balloon. After the initial inflation and stent deployment,
subsequent dilation with both low and high pressure balloons
optimizes results.
When awake and taking oral fluids, all patients were begun
on aspirin and dipyridamole. This therapy was continued for 6
months, after which all antithrombotic therapy was discontin-
ued. If an additional stent was implanted at repeat catheter-
ization, aspirin and dipyridamole were restarted for an addi-
tional 6 months.
In accordance with the FDA protocol, all patients had a full
outpatient evaluation, including a chest X-ray film, an electro-
cardiogram and, when applicable, an echocardiogram. In ad-
dition, patients with precatheterization evidence of unilateral
PA stenosis underwent a radionuclide lung perfusion study.
After the procedure, the patients were hospitalized overnight
to observe vascular access sites, to receive 4 doses of intrave-
nous cefazolin and to monitor cardiopulmonary stability. The
morning after catheterization, a chest X-ray film, an echocar-
diogram and, if applicable, a follow-up lung perfusion study
were obtained (only in patients with unilateral stenoses).
Intially, follow-up in all patients consisted of an outpatient
evaluation, a chest X-ray film and an electrocardiogram. Later
in the study, the 3- and 6-month post-stent evaluations were
tailored according to the clinical status of the patient. Cardiac
catheterization and, when applicable, lung perfusion studies
were scheduled 12 months after stent implantation. Data
collection points were defined as pre-implantation, postim-
plantation and follow-up catheterization.
At the initial catheterization and at all follow-up catheter-
izations or interventions, the data collected included the
stenosis location and diameter, the adjacent vessel diameter,
the pressure proximal and distal to the stenosis (gradient) and,
when applicable, the ratio of RV systolic pressure indexed to a
simultaneous femoral artery (FA) systolic pressure (RV/FA
ratio). The development of neointima within the stent was
assessed at follow-up catheterization by the separation of the
column of contrast from the stent wall during vessel imaging.
The patients were classified into three groups based on the
type and location of the stenoses. The first group had PA
stenoses after previous surgical palliation or repair. The sec-
ond group included patients with congenital PA stenoses. The
third group included patients with systemic vein stenoses,
including stenoses of postsurgical venous anastomoses (Table
1).
Statistical analysis. Statistical analysis was used to validate
the sample size but should not suggest clinical success or
failure of the procedure. Success in this patient group can
Abbreviations and Acronyms
ANOVA 5 analysis of variance
FA 5 femoral artery
FDA 5 Food and Drug Administration
IDE 5 investigational device exemption
PA 5 pulmonary artery
RV 5 right ventricle, right ventricular
RV/FA 5 right ventricular pressure indexed to femoral artery
pressure ratio
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further be defined by pressure gradients ,10 mm Hg in the
postoperative and congenital PA anastomoses groups. In the
systemic vein stenoses/venous anastomoses group, where initial
pressure gradients were small to absent, success was defined by
a significant increase in the diameter of the vessel. Statistical
significance across the study period was evaluated by analysis
of variance (ANOVA). On selected comparisons, the paired
two-tailed Student t test was used. Because of the large number
of patients, statistical significance was defined at p , 0.001.
Data are expressed as the mean value 6 SD. Graphic repre-
sentation of data is presented as the mean value 6 SEM.
Results
Demographic data. The study group consisted of 116 males
and 84 females. The geographic distribution of patients in-
cluded 38% from Houston, 33% from other institutions within
Texas, 25% from outside Texas and 4% from outside the
United States. The patients’ median age at stent implantation
was 10.5 years (range 6 months to 43 years), and the median
weight was 28 kg (range 5.3 to 83) (Fig. 1). Diagnoses and
previous surgical procedures are described in Table 1. The
longest follow-up was 62 months after stent implantation, with
a mean follow-up of 19 6 15 months. Of the patients who were
at least 1 year status post-stent implantation, follow-up cathe-
terization was performed at a mean of 14 months after
implantation.
Pulmonary artery stenoses. The 136 patients in the post-
operative PA stenoses group accounted for the largest number
of stents (237) placed in the PAs. In this group, the systolic
pressure gradient decreased from 46 6 25 to 10 6 12.8 mm Hg
after stent implantation and dilation (p , 0.001). There were
152 stenotic lesions with postimplant gradients ,10 mm Hg.
Data on 75 patients (112 stents) illustrated a slight pressure
gradient increase at follow-up catheterization to 13 6
14.2 mm Hg (p 5 0.006). The decrease in gradient from the
prestent measurement to the gradient at follow-up was statis-
tically significant (p , 0.001 by ANOVA). In the patients with
higher pressure gradients at follow-up, further dilation of the
stent decreased the mean gradient from 19 6 15.7 to 6 6
7.3 mm Hg (p , 0.001) (Fig. 2A).
In the 15 patients with congenital PA stenoses, there was a
similar immediate decrease in the pressure gradient (from
71 6 45 to 15 6 20 mm Hg, p , 0.001) (Fig. 2D). At follow-up
catheterization of seven patients, data on 14 stents revealed an
increase in the gradient compared with the post-stent measure-
ment (21 6 17 mm Hg), but this was not statistically significant
(p 5 0.2). In patients with higher gradients at follow-up,
further dilation of the stent resulted in a statistically significant
decrease in the gradient (from 34 6 9.8 to 19 6 14.6 mm Hg,
p , 0.001).
In both the postoperative and congenital PA stenoses
groups, vessel diameters increased markedly: the initial in-
crease was statistically significant in both groups (from 5.6 6
2.6 to 12.1 6 3.0 mm, p , 0.001 and from 3.3 6 1.2 to 8.9 6
1.2 mm, p , 0.001, respectively). Alternatively, this was a
.100% increase in diameter in 65% of the procedures in the
postoperative and 88% in the congenital PA stenoses groups.
There was a .200% increase in diameter in .50% of the
congenital PA stenoses group. At follow-up there was a small
decrease in diameter in both groups (postoperative PA steno-
ses group: 11.0 6 2.8 mm, p 5 0.0007; congenital PA stenoses
group: 7.9 6 2.1 mm, p 5 0.12). Although the 1-mm decrease
in diameter seen in both groups at follow-up did reach
statistical significance in the larger postoperative PA stenoses
group, it had no significant effect on the gradient. In both
groups, those stents/vessels which were further dilated had an
increase in diameter that did not reach our defined level of
statistical significance (postoperative PA stenoses group: from
9.6 6 2.8 to 12.3 6 3.4 mm, p 5 0.01; congenital PA stenoses
group: from 6.7 6 0.8 to 8.8 6 1.0 mm, p 5 0.006) (Fig. 2, B
and E).
Figure 1. Age and weight distributions of patients. y/o 5 years old.
Table 1. Diagnoses and Previous Surgical Interventions
Postoperative branch PA stenoses
Tetralogy of Fallot
s/p RVOT augmentaton 55
s/p systemic to PA shunt 17
s/p RV to PA conduit 9
With absent right or left PA 6
Pulmonary atresia
s/p RV to PA conduit 17
s/p systemic to PA shunt 8
s/p RVOT augmentation 8
Transposition of the great arteries
s/p arterial switch operation 7
With VSD, s/p RV to PA conduit 3
Truncus arteriosus s/p RV to PA conduit 8
VSD s/p PA band 6
Other diagnoses, s/p systemic to PA shunt 13
Congenital branch PA stenosis 15
Venous stenoses
s/p Fontan and Fontan variants for tricuspid atresia, previous shunts 10
s/p Fontan and Fontan variants (various diagnoses) 12
s/p Glenn/bidirectional Glenn (various diagnoses) 9
Atrial switch for transposition of the great arteries 7
Superior vena cava stenosis (various diagnoses) 5
Systemic venous stenoses 5
Data are presented as number of patients. PA 5 pulmonary artery; RV 5
right ventricle; RVOT 5 right ventricular outflow tract; s/p 5 status post; VSD 5
ventricular septal defect.
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The RV/FA systolic pressure ratio improved in both groups.
The RV systolic pressure in the postoperative PA stenoses
group decreased to less than half systemic (RV/FA: from
0.63 6 0.2 to 0.41 6 0.02, p , 0.001). This decrease persisted
at follow-up catheterization (0.45 6 0.01, p 5 0.002). In
patients who required further stent dilation, the RV/FA pres-
sure ratio decreased again (from 0.48 6 0.14 to 0.38 6 0.09,
p 5 0.2). (Fig. 2C). In the congenital PA stenoses group, a
drop in the RV/FA pressure ratio also occurred, although this
change was not statistically significant (from 0.71 6 0.3 to
0.55 6 0.35, p 5 0.04) (Fig. 2F). At follow-up catheterization,
the RV/FA pressure ratio in the congenital PA stenoses group
increased to 0.65 6 0.3 (p 5 0.8). Further dilation of stents in
a limited number of the patients with congenital PA stenoses
decreased the ratio from 0.74 6 0.15 to 0.70 6 0.14 (p 5 0.2),
which was not statistically significant.
Venous stenoses. The systemic vein stenoses/venous anas-
tomoses group included patients with stents placed in low
pressure–low velocity flow locations. These locations included
clinically and/or hemodynamically significant stenoses in sys-
temic veins, in atrial baffles or conduits or in the branch PAs
and veno-pulmonary artery anastomoses of the patient with a
postoperative cavopulmonary anastomosis. Eighty stents were
placed in 49 patients. Although initial pressure gradients in the
venous stenoses were much lower than those in both the
postoperative and congenital stenoses, after stent implantation
there was still a statistically significant decrease in the pressure
gradient (from 7 6 6.4 to 1 6 1.9 mm Hg, p , 0.001). At
follow-up catheterization of 13 patients (22 stents), there was
no statistically significant difference in the gradient (1 6
2.2 mm Hg, p 5 0.9). Five stents were further dilated; the
gradient decreased (from 4 6 3.3 to 1 6 0.8 mm Hg), but
this change did not reach statistical significance (p 5 0.06)
(Fig. 3A).
The diameter of the stenotic segment increased dramati-
cally after venous stent implantation (from 2.8 6 3.6 to 12.5 6
3.9 mm, p , 0.001). Twelve of the venous stenoses (18%) were
totally occluded vessels before stent implantation. Stent im-
Figure 2. A series of plots illustrating
changes in pressure gradients, diame-
ters and RV/FA ratios. A to C show
plots for patients with postoperative
PA stenoses; D to F show plots for
patients with congenital PA stenoses.
The use of “n” in the gradient and
diameter plots reflects measurements
available for individual stents, whereas
“n” in the RV/FA ratio plots refers to
patients (mean 6 SEM, *p , 0.001).
664 SHAFFER ET AL. JACC Vol. 31, No. 3
INTRAVASCULAR STENTS IN CONGENITAL HEART DISEASE March 1, 1998:661–7
plantation resulted in a .100% increase in diameter in 80% of
the procedures (55% of procedures had a .200% increase in
diameter). At follow-up catheterization there was a small
decrease in diameter (11.1 6 3.8 mm), which did reach
statistical significance (p 5 0.001), although there was no
apparent change in flow through the stents (Fig. 3B).
Lung perfusion studies. Improvement in perfusion to an
affected area after stent implantation was best quantitated in
patients with unilateral PA stenoses. There were 42 patients
who met this criterion. In these patients, the percentage of
perfusion to the affected lung increased from 31 6 17% to
46 6 14% after stent implantation (p , 0.001). This increase
remained unchanged on the follow-up perfusion scan (47 6
17%, p 5 0.2) (Fig. 4).
Complications. Morbidity. Early in our experience, there
were four instances of stent migration. Two of these stents
were surgically removed, and the other two were “captured”
and expanded in a benign position other than the original,
intended site. Three patients developed thrombosis of the PA
within the stent. All three of these patients had postoperative
cavopulmonary anastomoses. Two of the three patients had
significant pulmonary vein stenosis on the side of the throm-
bosis that was noted only after stent implantation. The third
patient had a previously diagnosed right atrial thrombus that
extended into the stent after implantation in spite of antico-
agulation. There were no episodes of systemic embolization or
thrombosis.
Stent implantation is subject to the same complications as
balloon angioplasty. Three patients developed retroperitoneal
hemorrhage, presumably due to multiple, large sheaths, cath-
eters and/or balloons in the iliac vessels. One patient required
laparoscopic evacuation of the hematoma. Self-limited hemop-
tysis occurred in four patients. This was thought to be second-
ary to tiny vascular ruptures not appreciated on angiography or
an acute increase of perfusion to the affected segment after
stent deployment (with rupture of a small distal vessel into the
alveoli). In one patient during repeat stent dilation, the balloon
within the stent “milked” distally and a PA laceration occurred
distal to the stent. A pedunculated aneurysm with a stenotic
mouth developed and has remained contained by the lung
parenchyma without treatment. Follow-up magnetic resonance
imaging approximately 6 months after the catheterization
revealed a decrease in aneurysm size.
Mortality. There were two deaths directly attributed to the
stent procedure. In one patient with unusual familial congen-
ital PA branch stenosis and suprasystemic PA pressure, dila-
tion and stent implantation into two small distal pulmonary
segments were successful. After the procedure, the increase in
flow to the stented lung segments became so great that severe
segmental pulmonary edema developed with a progressive and
lethal ventilation-perfusion mismatch. The second death was in
a small child 7 weeks status post tetralogy of Fallot repair with
severe residual bilateral branch PA stenosis. He had intracta-
ble right heart failure and was not considered a candidate for
reoperation. During stent dilation, there was a main PA tear
resulting in a massive hemothorax and the patient died. There
have been no late deaths related to the stents.
Discussion
As reported in earlier reports on this series and in several
other smaller series, the results of intravascular stents for
patients with congenital heart disease have been superb (4–8).
This report summarizes this single institution’s 6 years of
experience during the FDA phase one and two clinical trials of
the Palmaz stent in congenital heart disease. In our experience,
excellent results occur immediately after stent implantation
and at follow-up catheterization; neither the vessel stenoses
nor the pressure gradients return. Furthermore, in those
patients with residual pressure gradients or initial suboptimal
vessel diameters, further dilation of the stents can be safely and
effectively accomplished.
Figure 3. Pressure gradients and diameter changes in patients who
had stents implanted in low pressure systems—that is, systemic vein
stenoses/venous anastomoses (mean 6 SEM, *p , 0.001).
Figure 4. In postoperative and congenital PA stenoses, radionuclide
lung perfusion scan results are plotted across the study period (mean 6
SEM, *p , 0.001).
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Technical limitations of intravascular stents. The majority
of our patients with stents are older children and young adults.
A relative patient size (age and weight) limitation exists,
mainly because of the use of the 11F sheath needed for the
smooth delivery of model P-308 “iliac” stent. With improved
balloon technology, smaller sheaths may be used for stent
delivery, allowing smaller patients to undergo this procedure.
We have used 8F sheaths for the delivery of model P-204
“renal” stents into more distal, smaller vessels. We have
avoided using these smaller stents in proximal or central
vessels, even in infants or small children, because these stents,
limited to 8 to 10 mm maximal diameter, would themselves
create a fixed, nondilatable stenosis that would require surgical
opening or removal as the patient grows.
Further dilation of implanted stents. Previously published
reports have discussed the redilation of intravascular “iliac”
stents on a portion of this patient group (9,10). As the younger
patient grows, further dilation of the stent will be required
until the PA is of adequate size for an adult. Before this
current study, there was excellent animal data on further
dilation of implanted stents. Grifka et al. (11) reported success
in further dilation of stents in the aorta of growing mini-pigs
whose weights had increased by 400%. We report data on
patients who had successful further dilation of previously
implanted stents in a variety of locations and lesions. This was
well tolerated, without complications, and resulted in a favor-
able anatomic and hemodynamic response.
In patients who have had repeat catheterization, our redi-
lation protocol has been somewhat patient specific. If a high
gradient is present, we routinely attempt further dilation of the
stent. This can sometimes be accomplished with lower pressure
angioplasty balloons but often requires higher pressure bal-
loons. In some patients with severe pulmonary insufficiency
that may be aggravated by even minimal stenoses or in patients
with discrete stenoses within the stent, we have been more
aggressive at attempting further dilation in the presence of
minimal gradients. Finally, as follow-up catheterizations oc-
curred per protocol, there have been patients with minimal
clinically or echocardiographically evident restenosis. When
minimal gradients were confirmed during catheterization, we
attempted to optimize stent diameters for future growth of the
patient.
In several patients, “redilation” data reflect additional
stents placed inside previously implanted stents for additional
support or further dilation of the initial stent. This is particu-
larly useful in right PA stents that are positioned directly
posterior to the aorta. Anteroposterior compression of the
stent in this position has occasionally occurred, resulting in an
oval distortion of the stent. The additional stent helps to
“round out” the original stent. In addition, this technique has
been helpful in stented vessels made oval after using two high
pressure angioplasty balloons to dilate a persistent stenosis.
The additional stent on a larger diameter balloon can “round
out” the vessel.
One group of patients where further dilation of existing
stents is particularly important includes those with congenital
PA stenosis. The response to the initial dilation of these vessels
is unpredictable and the vessels are not “protected” by sur-
rounding scar from a previous operation. During implantation
of the stent, it is expanded within the stenosis only to the
diameter of the adjacent vessel. This vessel usually is smaller
than normal for the patient’s size. The ability to safely further
dilate these stents at future catheterization allows a conserva-
tive approach by not having to overdilate with the initial
implant. It is our impression that vascular disruption is less
likely when these smaller vessels are initially stented to sub-
maximal diameters with standard, lower pressure angioplasty
balloons.
Limitations of the pediatric age range. Although gradients
are not age or weight specific, the size of both PAs and
systemic veins does increase as the patient grows. The stent
diameters presented here represent the spectrum of mean
diameters across the entire study group. Smaller patients will
have smaller post-stent implant diameters. Although norma-
tive values for PA radius/diameter have been published for
both angiographic and echocardiographic measures, there are
sparse data on expected values for patients with congenital
heart disease (12–16). No adjustment in data has been made to
account for comparison with age- and weight-specific norms.
However, the significant change in mean diameter demon-
strated by this data is dramatic and associated with hemody-
namic improvement and anecdotal improvement in the pa-
tient’s clinical status.
Neointimal proliferation. At follow-up catheterization
there has been a consistent 1- to 2-mm decrease in the lumen
diameter within the stent. This is due to “normal” neointimal
covering of the stent surface. One to two millimeters of
neointimal growth is insignificant in these patients, although
this same amount of neointima is a very significant problem in
(much smaller) coronary artery stents. This has prompted
extensive discussion in the adult cardiology data about the
implications of neointimal proliferation as well as speculation
about its cause (17,18). Of the entire 200 patients, there were
only three (1.5%) with significant stenosis due to neointimal
proliferation. Each of these three patients has some peculiarity
of the vascular anatomy or the nature of the stent implant, or
both, that probably explains their unusual intimal reaction to
the stent. In a few of our patients, a larger amount of
neointimal proliferation was noted where the native vessel
diameter immediately proximal or distal to the stent was less
than the stent diameter. There was increased neointimal
proliferation immediately proximal and distal to any residual
stenosis (“waist”) within the stent. Thus, intimal build-up
appears to occur so that the entire vessel will remold to a
uniform diameter. Intraluminal wall irregularities that result in
turbulent flow are “smoothed out” during the endothelializa-
tion process. In 12 patients who have had two or more repeat
catheterizations at least 2 to 5 years after the initial stent
implantation, there was no further progression of neointimal
thickening once the internal diameter of the vessel had become
uniform.
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Modifications in thrombosis prevention. On the conclu-
sion of the protocol, some of the investigators now use only
aspirin for thrombosis prevention in patients who are not
taking oral anticoagulants for other reasons.
Conclusions. The results of this data obtained during the
FDA clinical trial indicate that intravascular stents are an
effective and safe therapy for the treatment of vascular steno-
ses in patients with congenital heart disease. There appears to
be no long-term morbidity associated with this device or the
procedure. Follow-up will continue to provide data on any
unexpected very long-term complications that may occur.
We acknowledge Sherri McSpadden for aid in both data collection and manage-
ment, as well as preparation of the manuscript.
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